Vertex Pharmaceuticals (VRTX)
Develops cystic fibrosis medicines, gene-edited cell therapy, and non-opioid pain treatment.
$514.79
vs last close−0.20 (−0.04%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 96.07% | 243.49M shares | |
|---|---|---|---|
| 1,821 holders · as of Jun 30, 2026 | |||
| Insiders | 0.22% | 568.2K shares | |
| 23 holders · as of Sep 10, 2026 | |||
| Other | 3.71% | 9.40M shares | |
| remainder | |||
253.46M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
1,821 holders · 243.49M shares · 194 new positions · 899 increased · 628 reduced · 132 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Capital World Investors | 26.12M | 10.30% | +746.9K | Aug 12, 2026 |
| BlackRock, Inc. | 24.11M | 9.51% | +139.9K | Aug 7, 2026 |
| Capital Research Global Investors | 19.49M | 7.69% | −1.64M | Aug 12, 2026 |
| Vanguard Capital Management LLC | 16.58M | 6.54% | +67.9K | Aug 13, 2026 |
| State Street Corp | 11.87M | 4.68% | +141.3K | Aug 7, 2026 |
| Invesco Ltd. | 8.04M | 3.17% | +2.71M | Aug 14, 2026 |
| JPMorgan Chase & Co | 6.52M | 2.57% | −515.6K | Aug 12, 2026 |
| Geode Capital Management, LLC | 6.02M | 2.37% | −121.8K | Aug 12, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Capital World Investors | 10.10% | 25.70M | 13G | May 14, 2026 |
| Capital Research Global Investors | 8.30% | 21.14M | 13G | May 14, 2026 |
| Vanguard Capital Management | 7.49% | 19.04M | 13G | Apr 30, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 2, 2026 | Duncan McKechnieofficer: EVP, Chief Commercial Officer | Sale | 1,541 | $519.00 | 11,001 |
| Jul 2, 2026 | Ourania Tatsisofficer: EVP, Chief Reg. & Quality Off. | Sale | 1,500 | $524.99 | 45,321 |
| Jul 1, 2026 | Joy Liuofficer: EVP and Chief Legal Officer | Sale | 828 | $502.71 | 19,131 |
| Jun 26, 2026 | Carmen Bozicofficer: EVP and CMO | Sale | 596 | $482.50 | 15,337 |
| Jun 18, 2026 | Carmen Bozicofficer: EVP and CMO | Sale | 1,020 | $462.17 | 15,933 |
| Jun 15, 2026 | Carmen Bozicofficer: EVP and CMO | Sale | 4,062 | $450.00 | 16,953 |
| Jun 5, 2026 | Carmen Bozicofficer: EVP and CMO | Sale | 1,745 | $450.00 | 21,015 |
| May 29, 2026 | Carmen Bozicofficer: EVP and CMO | Sale | 1,974 | $450.00 | 22,760 |
| May 15, 2026 | Carmen Bozicofficer: EVP and CMO | Sale | 1,354 | $453.45 | 24,734 |
| May 15, 2026 | Mark E. Bunnageofficer: EVP, Chief Scientific Officer | Sale | 33 | $453.45 | 7,284 |
House and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Rep. David J. Taylor · OH02 | Sale (Full) | $1,001 – $15,000 | Aug 26, 2026 | Sep 7, 2026 | |
| Rep. David Taylor · OH02 | Sale | $1,001 – $15,000 | Aug 26, 2026 | Sep 7, 2026 | |
| Rep. David J. Taylor · OH02 | Sale (Full) | $1,001 – $15,000 | Aug 25, 2026 | Sep 7, 2026 | |
| Sen. Alan Armstrong | Purchase | $1,001 – $15,000 | Joint | Mar 27, 2026 | Jul 21, 2026 |
| Rep. Ro Khanna · CA17 | Purchase | $1,001 – $15,000 | Spouse | Apr 13, 2026 | May 13, 2026 |